Vincent Haghnejad1, Catherine Le Berre1, Yoann Dominique2, Camille Zallot1, Francis Guillemin2, Laurent Peyrin-Biroulet3. 1. Department of Gastroenterology, Nancy University Hospital, Université de Lorraine, Vandœuvre-lès-Nancy, France. 2. CIC-1433 Clinical Epidemiology, Nancy University Hospital, Inserm, Université de Lorraine, Vandœuvre-lès-Nancy, France. 3. Department of Gastroenterology, Nancy University Hospital, Université de Lorraine, Vandœuvre-lès-Nancy, France. Electronic address: peyrinbiroulet@gmail.com.
Abstract
BACKGROUND: To lighten the burden on health-care spending, switching from the infliximab originator to a biosimilar in patients with inflammatory bowel disease (IBD) is advocated. However, the uptake of biosimilars lacks initiatives aimed at educating patients. AIMS: To explore the impact of a gastroenterologist's interview on IBD patients' acceptance for switching from infliximab bio-originator Remicade® to its biosimilar CT-P13 Inflectra®. METHODS: After the interview of 138 included patients, 120 properly responded to a self-administered questionnaire to collect consent about the switch and relevant data. French national IBD patients' association (Association François Aupetit) provided an information sheet on biosimilars. RESULTS: 93 (67.0%) out of 138 and 82 (68.3%) out of 120 patients switched treatment. 114 (79.8%) had never heard about biosimilars. Paradoxically, having heard about biosimilars was associated with a poorer chance to switch (Odds Ratio OR [95% CI] = 0.13 [0.02-0.72]). On the contrary, the more satisfied about generics, the more patients accepted the switch (OR [95% CI] = 1.31 [1.01-1.69]). There were 1.47 (Relative Risk RR [95% CI] = 1.47 [1.07-2.01]) times more chance to agree to the switch if the interview modified the patient's opinion on biosimilars. CONCLUSION: This study confirms that an organized information provided to the patient is a contributive way to enhance patient's acceptance of biosimilars in IBD.
BACKGROUND: To lighten the burden on health-care spending, switching from the infliximab originator to a biosimilar in patients with inflammatory bowel disease (IBD) is advocated. However, the uptake of biosimilars lacks initiatives aimed at educating patients. AIMS: To explore the impact of a gastroenterologist's interview on IBDpatients' acceptance for switching from infliximab bio-originator Remicade® to its biosimilar CT-P13 Inflectra®. METHODS: After the interview of 138 included patients, 120 properly responded to a self-administered questionnaire to collect consent about the switch and relevant data. French national IBDpatients' association (Association François Aupetit) provided an information sheet on biosimilars. RESULTS: 93 (67.0%) out of 138 and 82 (68.3%) out of 120 patients switched treatment. 114 (79.8%) had never heard about biosimilars. Paradoxically, having heard about biosimilars was associated with a poorer chance to switch (Odds Ratio OR [95% CI] = 0.13 [0.02-0.72]). On the contrary, the more satisfied about generics, the more patients accepted the switch (OR [95% CI] = 1.31 [1.01-1.69]). There were 1.47 (Relative Risk RR [95% CI] = 1.47 [1.07-2.01]) times more chance to agree to the switch if the interview modified the patient's opinion on biosimilars. CONCLUSION: This study confirms that an organized information provided to the patient is a contributive way to enhance patient's acceptance of biosimilars in IBD.